$4.21
5.78% today
Nasdaq, Nov 10, 10:00 pm CET
ISIN
US00847G7051
Symbol
AGEN

Agenus Inc. Stock price

$4.21
+0.24 6.05% 1M
+0.71 20.29% 6M
+1.47 53.65% YTD
+0.31 7.95% 1Y
-43.87 91.24% 3Y
-77.24 94.83% 5Y
-87.05 95.39% 10Y
-583.40 99.28% 20Y
Nasdaq, Closing price Mon, Nov 10 2025
+0.23 5.78%
ISIN
US00847G7051
Symbol
AGEN
Industry

Key metrics

Basic
Market capitalization
$126.8m
Enterprise Value
$151.9m
Net debt
$25.1m
Cash
$9.5m
Shares outstanding
30.0m
Valuation (TTM | estimate)
P/E
negative | 3.3
P/S
1.2 | 0.8
EV/Sales
1.5 | 0.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-144.2%
Return on Equity
69.7%
ROCE
185.3%
ROIC
-
Debt/Equity
-0.1
Financials (TTM | estimate)
Revenue
$101.7m | $166.1m
EBITDA
$-78.5m | $-148.1m
EBIT
$-91.4m | $62.2m
Net Income
$-165.7m | $36.1m
Free Cash Flow
$-127.9m
Growth (TTM | estimate)
Revenue
-36.3% | 60.5%
EBITDA
20.7% | -33.3%
EBIT
19.6% | 150.0%
Net Income
25.9% | 115.9%
Free Cash Flow
31.3%
Margin (TTM | estimate)
Gross
99.4%
EBITDA
-77.2% | -89.2%
EBIT
-89.9%
Net
-162.9% | 21.8%
Free Cash Flow
-125.7%
More
EPS
$-5.9
FCF per Share
$-4.3
Short interest
6.2%
Employees
316
Rev per Employee
$330.0k
Show more

Is Agenus Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Agenus Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Agenus Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Agenus Inc. forecast:

Buy
78%
Hold
22%

Financial data from Agenus Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
102 102
36% 36%
100%
- Direct Costs 0.64 0.64
19% 19%
1%
101 101
36% 36%
99%
- Selling and Administrative Expenses 69 69
6% 6%
68%
- Research and Development Expense 123 123
38% 38%
121%
-78 -78
21% 21%
-77%
- Depreciation and Amortization 13 13
12% 12%
13%
EBIT (Operating Income) EBIT -91 -91
20% 20%
-90%
Net Profit -166 -166
26% 26%
-163%

In millions USD.

Don't miss a Thing! We will send you all news about Agenus Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agenus Inc. Stock News

Neutral
Business Wire
about 10 hours ago
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spann...
Neutral
Business Wire
5 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financial results before the market opens on Monday, November 10, 2025. The company also plans to host a stakeholder briefing webcast in late November to provide a corporate and clinical development update. ...
Neutral
Seeking Alpha
20 days ago
Agenus Inc. (NASDAQ:AGEN ) Shareholder/Analyst Call October 21, 2025 4:00 PM EDT Company Participants Stefanie Perna-Nacar - Chief Communications & Government Relations Officer Garo Armen - Founder, Executive Chairman & CEO Richard Goldberg - Chief Development Officer Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Conference Call Participants Michael S. Gordon Alex...
More Agenus Inc. News

Company Profile

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Head office United States
CEO Garo Armen
Employees 316
Founded 1994
Website agenusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today